MediWound Ltd. (MDWD) Raised to Sell at ValuEngine
MediWound Ltd. (NASDAQ:MDWD) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.
A number of other analysts have also weighed in on the stock. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $10.00 target price on shares of MediWound in a report on Monday, September 18th. Zacks Investment Research lowered shares of MediWound from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. SunTrust Banks, Inc. reiterated a “buy” rating on shares of MediWound in a report on Monday, June 26th. Cowen and Company assumed coverage on shares of MediWound in a report on Thursday, September 28th. They set an “outperform” rating and a $9.00 target price for the company. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $10.00 target price on shares of MediWound in a report on Thursday, September 28th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $9.15.
Shares of MediWound (MDWD) traded down 1.96% on Friday, reaching $5.00. The company’s stock had a trading volume of 20,825 shares. MediWound has a 12 month low of $4.25 and a 12 month high of $8.25. The stock has a 50 day moving average of $5.37 and a 200-day moving average of $6.33. The firm’s market cap is $109.77 million.
MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The business had revenue of $0.69 million for the quarter, compared to analysts’ expectations of $0.69 million. During the same quarter in the previous year, the company earned ($0.34) earnings per share. The business’s quarterly revenue was up 93.8% on a year-over-year basis. On average, analysts anticipate that MediWound will post ($0.76) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “MediWound Ltd. (MDWD) Raised to Sell at ValuEngine” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/22/mediwound-ltd-mdwd-raised-to-sell-at-valuengine.html.
Institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its holdings in shares of MediWound by 19.7% during the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after purchasing an additional 8,745 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of MediWound by 1.7% during the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 1,300 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of MediWound by 20.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after purchasing an additional 342,165 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in shares of MediWound by 11.0% during the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after purchasing an additional 213,745 shares during the period. Institutional investors own 19.55% of the company’s stock.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.